Jacobi Capital Management LLC Acquires 203 Shares of Zoetis Inc. (NYSE:ZTS)

Jacobi Capital Management LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 2.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,978 shares of the company’s stock after purchasing an additional 203 shares during the period. Jacobi Capital Management LLC’s holdings in Zoetis were worth $1,463,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Atlantic Edge Private Wealth Management LLC grew its holdings in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the period. Darwin Wealth Management LLC bought a new stake in shares of Zoetis in the third quarter worth $31,000. First Personal Financial Services bought a new stake in shares of Zoetis in the third quarter worth $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis in the third quarter worth $33,000. Finally, Dunhill Financial LLC grew its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $167.58 on Friday. The stock’s 50-day simple moving average is $166.30 and its 200-day simple moving average is $177.30. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The company has a market capitalization of $75.04 billion, a price-to-earnings ratio of 30.64, a PEG ratio of 2.78 and a beta of 0.90. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. Zoetis’s payout ratio is 36.56%.

Analysts Set New Price Targets

Several analysts recently commented on the company. StockNews.com lowered Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Piper Sandler lifted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Leerink Partners initiated coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Finally, Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $215.90.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.